Galecto, Inc. is a biotech company that develops molecules to treat fibrosis, cancer, inflammation, and related diseases. Their lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. They also have other treatments in development, including GB0139 and GB1211, which are in Phase IIb and Phase IIa/Phase Ib clinical trials, respectively.